CJC-1295 (No DAC) + Ipamorelin Product Brief

Ready-to-Sell Research Product Sheet

1. Stack Overview

CJC-1295 (No DAC) combined with Ipamorelin is a commonly researched peptide stack designed to study growth hormone signaling pathways.

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH), while Ipamorelin is a selective ghrelin receptor agonist. Together, the peptides are studied for their complementary effects on stimulating endogenous growth hormone release while maintaining a pulsatile hormone pattern.

2. Mechanism of Interest

This peptide combination is studied for several complementary biological mechanisms:

• CJC-1295 (No DAC) stimulates the GHRH receptor to promote growth hormone release
  • Ipamorelin activates the ghrelin receptor (GHS-R1a)
  • The combination may support natural pulsatile GH secretion
  • Potential increase in IGF-1 signaling pathways
  • May influence metabolic, recovery, and regenerative research pathways

3. Research Areas Being Explored

• Growth hormone pulsation research
  • Body composition studies
  • Recovery and regeneration pathways
  • Sleep and endocrine signaling research
  • Metabolic regulation studies

4. Suggested Research Vial Sizes

• 5 mg / 5 mg dual vial kit
  • 10 mg / 10 mg dual vial kit
  • 10 mg / 5 mg research kit
  • 20 mg / 10 mg professional research kit

5. Example Reconstitution Chart

Example mixing protocols commonly used in research contexts:

CJC-1295 (No DAC)
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL concentration

Ipamorelin
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL concentration

These concentrations allow accurate measurement using insulin syringes for laboratory research settings.

6. Label Information for Vials

• Peptide names: CJC-1295 (No DAC) and Ipamorelin
  • Total amount per vial (mg)
  • Lot / batch number
  • Manufacturing date
  • Storage instructions (2–8°C recommended)
  • Research use only disclaimer

7. Market Positioning

CJC-1295 (No DAC) with Ipamorelin is commonly positioned in the growth hormone research peptide category.

It is frequently marketed for research exploring:

• Growth hormone pulsation models
  • Recovery and regenerative pathways
  • Body composition research
  • Metabolic and endocrine signaling studies

8. Example Research Stack Extensions

• CJC-1295 (No DAC) + Ipamorelin + BPC-157
  • CJC-1295 (No DAC) + Ipamorelin + TB-500
  • CJC-1295 (No DAC) + Ipamorelin + IGF-1 related peptides
  • CJC-1295 (No DAC) + Ipamorelin + Thymosin Alpha-1

9. Safety and Regulatory Notes

CJC-1295 (No DAC) and Ipamorelin are not approved by the FDA for medical treatment and are commonly distributed as research compounds.

This document is intended for informational and research product description purposes only.